Insulin Resistance, Type 2 Diabetes and Chronic Liver Disease. A Deadly Trio
Amedeo Lonardo and Paola Loria
University of Modena and Reggio Emilia Department of Internal Medicine, Endocrinology, Geriatrics Nuovo Ospedale Sant’Agostino Estense di Baggiovara, Baggiovara, Modena, Italy.
Abstract
In this commentary to the paper by Donadon V. et al (Clinical Medicine: Endocrinology and Diabetes. 2009;2:25–33.) the association and significance of insulin resistance with chronic liver disease are shortly reviewed and the molecular mechanisms underlying the diabetogenic and oncogenic potentials of advanced liver disease are summarized. Literature studies demonstrate that hepatocellular carcinoma (HCC) can be part of the natural history of NASH. HCCs in patients with features of metabolic syndrome as the only risk factor for liver disease have distinct morphological characteristics and mainly occur in the absence of significant fibrosis in the background liver. Moreover, data indicate that the presence of diabetes carries an approximately three to four-fold increased risk of HCC and such a risk is strongly increased by concurrent viral infections. Finally, the relationship between insulin resistance, steatosis and diabetes in NAFLD and HCV infection will be commented, along with the directions for future studies.
Readers of this also read:
- Insulin Resistance, Type 2 Diabetes and Chronic Liver Disease. A Deadly Trio
- Dynamics of the Vaginal Ecosystem—Hormonal Influences
- Dynamics of the Vaginal Ecosystem—Hormonal Influences
- Adjuvant Gemcitabine-Oxaliplatin (GEMOX) after Curative Surgery in High-risk Patients with Cholangiocarcinoma
- BITC Sensitizes Pancreatic Adenocarcinomas to TRAIL-induced Apoptosis